Fengsheng Che - Sihuan Pharmaceutical Chairman

SHPHFDelisted Stock  USD 0.1  0.00  0.00%   

Chairman

Dr. Che Fengsheng is Executive Chairman of the Board of the Company. He is a cofounder of the Group and is responsible for the overall management, strategic planning and business development of the Group and is instrumental to the Groups growth and business expansion since its establishment in 2001. Prior to the Groups establishment, Dr. Che had more than 8 years of experience as a medical doctorneurologist and 20 years of experience in the sales and marketing of pharmaceutical products and the management of pharmaceutical companies. From 1997 to 2001, Dr. Che was general manager of Hainan Kang Tong Pharmaceutical Co., Ltd where he was in charge of the companys overall management. From 1995 to 1997, Dr. Che was the assistant general manager and vice manager of Shenzhen City New Special Pharmaceutical Products Co., Ltd. where he was responsible for the marketing and overall management of the companys business. Between 1993 and 1995, Dr. Che was the product promotions manager of Shenzhen City Healthcare Pharmaceutical Company and East China Regional manager, in charge of sales and marketing. From 1991 to 1993, Dr. Che held the position of chief neurologist and lecturer in First Military Medical University, Zhu Jiang Hospital, Guangzhou City, PRC. Dr. Che was a neurologist and an assistant lecturer at the Fourth Military Medical University in Xian City, PRC from 1990 to 1991 and at the Fourth Military Medical University, Xi Jing Hospital in Xian City, PRC from 1984 to 1987 respectively. since 2014.
Age 61
Tenure 10 years
Professional MarksPh.D
Phone852 3628 3911
Webhttps://www.sihuanpharm.com
Che received his Bachelor of Medicine and Master of Medicine from the Fourth Military Medical University, Xi’an City, PRC, in 1984 and 1990 respectively. He also received an Executive MBA from China Europe International Business School in 1999.

Sihuan Pharmaceutical Management Efficiency

Sihuan Pharmaceutical's management efficiency ratios could be used to measure how well Sihuan Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.
Sihuan Pharmaceutical Holdings has accumulated 844.75 M in total debt with debt to equity ratio (D/E) of 0.14, which may suggest the company is not taking enough advantage from borrowing. Sihuan Pharmaceutical has a current ratio of 2.38, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Sihuan Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Sihuan Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sihuan Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sihuan to invest in growth at high rates of return. When we think about Sihuan Pharmaceutical's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 6 records

CHAIRMAN Age

Jack BendheimPhibro Animal Health
77
Judy SchmelingCanopy Growth Corp
60
Michael SingerAurora Cannabis
56
Ruben MinskiProcaps Group SA
72
Ronald FunkAurora Cannabis
63
Mark IwickiKala Pharmaceuticals
58
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in the Peoples Republic of China. The company was founded in 2001 and is based in Wanchai, Hong Kong. Sihuan Pharmaceutical operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 3896 people. Sihuan Pharmaceutical Holdings [SHPHF] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Sihuan Pharmaceutical Leadership Team

Elected by the shareholders, the Sihuan Pharmaceutical's board of directors comprises two types of representatives: Sihuan Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sihuan. The board's role is to monitor Sihuan Pharmaceutical's management team and ensure that shareholders' interests are well served. Sihuan Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sihuan Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Weicheng Guo, Deputy Chairman, CEO and Member of Nomination Committee
Xianhui Meng, Deputy General Manager of Sales and Marketing and Executive Director
Yanling Chen, Joint Director
Guili Miao, Chief CEO
Kin Li, Joint Sec
Fengsheng Che, Co-Founder, Executive Chairman and Member of Remuneration Committee
Jionglong Zhang, Non-Executive Director
Chengkon Shih, General Manager of Shandong Xuanzhu
Feng Guo, Executive Director

Sihuan Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Sihuan Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Other Consideration for investing in Sihuan Pink Sheet

If you are still planning to invest in Sihuan Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sihuan Pharmaceutical's history and understand the potential risks before investing.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Global Correlations
Find global opportunities by holding instruments from different markets
Stocks Directory
Find actively traded stocks across global markets